📣 VC round data is live. Check it out!

LeMaitre Vascular Valuation Multiples

Discover LeMaitre Vascular's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Axogen, Mehow Innovative, Establishment Labs, Jafron Biomedical and more.

LeMaitre Vascular Overview

About LeMaitre Vascular

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.


Founded

1983

HQ

United States

Employees

664

Financials (LTM)

Revenue: $262M
EBITDA: $81M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

LeMaitre Vascular Financials

LeMaitre Vascular reported last 12-month revenue of $262M and EBITDA of $81M.

In the same LTM period, LeMaitre Vascular generated $188M in gross profit, $81M in EBITDA, and $63M in net income.

Revenue (LTM)


LeMaitre Vascular P&L

In the most recent fiscal year, LeMaitre Vascular reported revenue of $250M and EBITDA of $91M.

LeMaitre Vascular is profitable as of last fiscal year, with gross margin of 72%, EBITDA margin of 36%, and net margin of 23%.

See analyst estimates for LeMaitre Vascular
LTMLast FY202320242025202620272028
Revenue$262M$250M$193M$220M$250M
Gross Profit$188M$179M$127M$151M$179M
Gross Margin72%72%66%69%72%
EBITDA$81M$91M$49M$67M$91M
EBITDA Margin31%36%25%30%36%
EBIT Margin27%27%19%24%27%
Net Profit$63M$58M$30M$44M$58M
Net Margin24%23%16%20%23%
Net Debt-$140M---

Financial data powered by Morningstar, Inc.

LeMaitre Vascular Stock Performance

LeMaitre Vascular has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


LeMaitre Vascular's stock price is $91.55.

LeMaitre Vascular share price decreased by 3.3% in the last 30 days, and increased by 10.2% in the last year.

LeMaitre Vascular has an EPS (earnings per share) of $2.53.

See more trading valuation data for LeMaitre Vascular
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B0.1%-3.3%-16.1%10.2%$2.53

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

LeMaitre Vascular Valuation Multiples

LeMaitre Vascular trades at 7.3x EV/Revenue multiple, and 23.5x EV/EBITDA.

See NTM and 2027E valuation multiples for LeMaitre Vascular

EV / Revenue (LTM)


LeMaitre Vascular Financial Valuation Multiples

As of June 3, 2026, LeMaitre Vascular has market cap of $2B and EV of $2B.

LeMaitre Vascular has a P/E ratio of 33.4x.

LTMLast FY202320242025202620272028
EV/Revenue7.3x7.7x9.9x8.7x7.7x
EV/EBITDA23.5x21.1x39.1x28.7x21.1x
EV/EBIT26.9x28.2x51.5x36.6x28.2x
EV/Gross Profit10.2x10.7x15.1x12.7x10.7x
P/E33.4x36.2x69.5x47.5x36.2x
EV/FCF25.5x25.7x64.9x51.5x25.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified LeMaitre Vascular Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

LeMaitre Vascular Margins & Growth Rates

LeMaitre Vascular grew revenue by 12% and EBITDA by 0% in the last fiscal year.

In the most recent fiscal year, LeMaitre Vascular reported gross margin of 72%, EBITDA margin of 36%, and net margin of 23%.

See estimated margins and future growth rates for LeMaitre Vascular

LeMaitre Vascular Margins

Last FY202420252026202720282029
Gross Margin72%69%72%72%
EBITDA Margin36%30%36%32%
EBIT Margin27%24%27%29%
Net Margin23%20%23%25%
FCF Margin30%17%30%28%

LeMaitre Vascular Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth12%14%14%12%
Gross Profit Growth13%19%18%13%
EBITDA Growth0%36%36%0%
EBIT Growth18%40%30%18%
Net Profit Growth20%46%31%20%
FCF Growth5%26%100%5%

Data powered by FactSet, Inc. and Morningstar, Inc.

LeMaitre Vascular Operational KPIs

LeMaitre Vascular's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

LeMaitre Vascular's Rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

LeMaitre Vascular's Rule of X is 63% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for LeMaitre Vascular
LTMLast FY202320242025202620272028
Rule of 4042%45%---
Bessemer Rule of X58%63%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue22%22%21%21%22%
G&A Expenses to Revenue17%17%16%16%17%
R&D Expenses to Revenue6%6%9%7%6%
Opex to Revenue-44%46%45%44%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

LeMaitre Vascular Competitors

LeMaitre Vascular competitors include Axogen, Mehow Innovative, Establishment Labs, Jafron Biomedical, Jeol, GN Store Nord, Elekta, Fukuda Denshi, MicroPort and Bausch Health.

Most LeMaitre Vascular public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Axogen9.0x8.3x77.9x70.1x
Mehow Innovative7.7x7.0x29.1x26.4x
Establishment Labs10.7x9.7x(159.9x)(2593.1x)
Jafron Biomedical6.5x6.3x13.3x13.2x
Jeol1.7x1.9x11.2x10.5x
GN Store Nord1.4x1.6x8.8x9.5x
Elekta1.5x1.5x11.4x10.8x
Fukuda Denshi1.8x1.8x6.6x-

This data is available for Pro users. Sign up to see all LeMaitre Vascular competitors and their valuation data.

Start Free Trial

Acquisitions by LeMaitre Vascular

LeMaitre Vascular has acquired 2 companies to date.

Last acquisition by LeMaitre Vascular was on June 22nd 2020. LeMaitre Vascular acquired Artegraft for $90M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by LeMaitre Vascular

Artegraft
Restore Flow Allografts
Description
Artegraft is a North Carolina manufacturer of biologic vascular grafts sourced from bovine carotid arteries. Headquartered in North Brunswick, New Jersey, the company produces tapered and straight grafts in diameters from 4mm to 20mm for hemodialysis access, peripheral bypass, and aortic reconstruction. Implanted in over 100,000 patients since FDA approval in 1984, Artegraft grafts feature glutaraldehyde fixation for durability and host tissue ingrowth.
Restore Flow Allografts is a Chicago-based healthcare firm incorporated in 2013, specializing in vascular allografts for peripheral artery disease treatment. Its RestoreFlow product line includes decellularized human placental arteries designed for hemodialysis access and below-the-knee bypass grafts, offering antimicrobial resistance and improved patency rates compared to synthetic alternatives.
HQ CountryUnited StatesUnited States
HQ City
North Brunswick, NJ
Chicago, IL
Deal Date22 Jun 202010 Nov 2016
Valuation$90M$14M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all LeMaitre Vascular acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About LeMaitre Vascular

When was LeMaitre Vascular founded?LeMaitre Vascular was founded in 1983.
Where is LeMaitre Vascular headquartered?LeMaitre Vascular is headquartered in United States.
How many employees does LeMaitre Vascular have?As of today, LeMaitre Vascular has over 664 employees.
Who is the CEO of LeMaitre Vascular?LeMaitre Vascular's CEO is George W. Lemaitre.
Is LeMaitre Vascular publicly listed?Yes, LeMaitre Vascular is a public company listed on Nasdaq.
What is the stock symbol of LeMaitre Vascular?LeMaitre Vascular trades under LMAT ticker.
When did LeMaitre Vascular go public?LeMaitre Vascular went public in 2006.
Who are competitors of LeMaitre Vascular?LeMaitre Vascular main competitors include Axogen, Mehow Innovative, Establishment Labs, Jafron Biomedical, Jeol, GN Store Nord, Elekta, Fukuda Denshi, MicroPort, Bausch Health.
What is the current market cap of LeMaitre Vascular?LeMaitre Vascular's current market cap is $2B.
What is the current revenue of LeMaitre Vascular?LeMaitre Vascular's last 12 months revenue is $262M.
What is the current revenue growth of LeMaitre Vascular?LeMaitre Vascular revenue growth (NTM/LTM) is 11%.
What is the current EV/Revenue multiple of LeMaitre Vascular?Current revenue multiple of LeMaitre Vascular is 7.3x.
What is the current EBITDA of LeMaitre Vascular?LeMaitre Vascular's last 12 months EBITDA is $81M.
What is LeMaitre Vascular's EBITDA margin?LeMaitre Vascular's last 12 months EBITDA margin is 31%.
What is the current EV/EBITDA multiple of LeMaitre Vascular?Current EBITDA multiple of LeMaitre Vascular is 23.5x.
What is the current FCF of LeMaitre Vascular?LeMaitre Vascular's last 12 months FCF is $75M.
What is LeMaitre Vascular's FCF margin?LeMaitre Vascular's last 12 months FCF margin is 29%.
What is the current EV/FCF multiple of LeMaitre Vascular?Current FCF multiple of LeMaitre Vascular is 25.5x.
How many companies LeMaitre Vascular has acquired to date?As of June 2026, LeMaitre Vascular has acquired 2 companies.
What was the largest acquisition by LeMaitre Vascular?$90M acquisition of Artegraft on 22nd June 2020 was the largest M&A LeMaitre Vascular has done to date.
What companies LeMaitre Vascular acquired?LeMaitre Vascular acquired Artegraft and Restore Flow Allografts.
In how many companies LeMaitre Vascular has invested to date?LeMaitre Vascular hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to LeMaitre Vascular

Lists including LeMaitre Vascular

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial